Investigational drug · Phase 3
SGT-003
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Duchenne Muscular Dystrophy, Advanced Solid Tumor.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "SGT-003"
First trial start
2025
Oct 22, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SGT-003", any sponsor or status.
Conditions studied
As listed on its trial records.
- Duchenne Muscular Dystrophy
- Advanced Solid Tumor
Approved drugs for the same conditions: Duchenne muscular dystrophy · Oncology · Neurology · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "SGT-003" as an intervention, largest first.
Beijing Sungen Biomedical Technology Co., LtdIndustry
NCT07811037 · 332 participants (planned) · Start Aug 17, 2026 · Primary completion Dec 2028
Drug: SGT003 · For: Advanced Solid Tumor
Sites: Beijing, China
- A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)Pivotal-lookingRecruiting
Solid Biosciences Inc.Industry
NCT07160634 · 80 participants (planned) · Start Oct 22, 2025 · Primary completion Jan 2029
Drug: SGT-003; Placebo · For: Duchenne Muscular Dystrophy
Sites: Little Rock, Arkansas; Flower Mound, Texas; Norfolk, Virginia · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Gene therapy in Duchenne muscular dystrophy.
Laugel V · Arch Pediatr 2025
Also in development for Duchenne Muscular Dystrophy
- AOC 1044Phase 33 trials
Avidity Biosciences, Inc. · DMD, Duchenne Muscular Dystrophy, Exon 44
- DeramiocelCAP-1002, Allogeneic Cardiosphere-Derived CellsPhase 32 trials
Capricor Inc. · Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic
- SevasemtenPhase 24 trials
Edgewise Therapeutics, Inc. · Becker Muscular Dystrophy, Duchenne Muscular Dystrophy
- BrogidirsenNS-089, NCNP-02Phase 23 trials
NS Pharma, Inc. · Duchenne Muscular Dystrophy, Exon 44, DMD
- BMN 351Phase 22 trials
BioMarin · Duchenne Muscular Dystrophy (DMD), Duchenne Muscular Dystrophy
- SAT-3247Phase 22 trials
Satellos Bioscience, Inc. · Duchenne Muscular Dystrophy, Duchenne, DMD
- WVE-N531Phase 22 trials
Wave Life Sciences USA, Inc. · Duchenne Muscular Dystrophy
- NS-050NCNP-03Phase 21 trial
NS Pharma, Inc. · Duchenne Muscular Dystrophy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.